John H. Sampson, M.D., Ph.D. - Publications

Affiliations: 
Surgery, Immunology, Pathology, Radiation Oncology Duke Medical School, Durham, NC, United States 
Area:
translational immunotherapy, EGFR-tyrosine kinase inhibitor ZD1839
Website:
http://neuro.surgery.duke.edu/faculty/details/0108354

352 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Mohan AA, Tomaszewski WH, Haskell-Mendoza AP, Hotchkiss KM, Singh K, Reedy JL, Fecci PE, Sampson JH, Khasraw M. Targeting Immunometabolism in Glioblastoma. Frontiers in Oncology. 11: 696402. PMID 34222022 DOI: 10.3389/fonc.2021.696402  1
2021 Ellingson BM, Sampson JH, Achrol AS, Aghi MK, Krystof Bankiewicz K, Wang C, Bexon M, Brem S, Brenner AJ, Chowdhary S, Floyd JR, Han SJ, Kesari S, Randazzo D, Vogelbaum MA, et al. Modified RANO (mRANO), iRANO, and standard RANO response to convection-enhanced delivery of IL4R-targeted immunotoxin MDNA55 in recurrent glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33863808 DOI: 10.1158/1078-0432.CCR-21-0446  0.01
2021 Swartz AM, Congdon KL, Nair SK, Li QJ, Herndon JE, Suryadevara CM, Riccione KA, Archer GE, Norberg PK, Sanchez-Perez LA, Sampson JH. A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope. Npj Vaccines. 6: 12. PMID 33462231 DOI: 10.1038/s41541-020-00273-5  1
2021 Gromeier M, Brown MC, Zhang G, Lin X, Chen Y, Wei Z, Beaubier N, Yan H, He Y, Desjardins A, Herndon JE, Varn FS, Verhaak RG, Zhao J, Bolognesi DP, ... ... Sampson JH, et al. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nature Communications. 12: 352. PMID 33441554 DOI: 10.1038/s41467-020-20469-6  1
2020 Brady M, Raghavan R, Sampson J. Determinants of Intraparenchymal Infusion Distributions: Modeling and Analyses of Human Glioblastoma Trials. Pharmaceutics. 12. PMID 32967184 DOI: 10.3390/Pharmaceutics12090895  1
2020 Gedeon PC, Champion CD, Rhodin KE, Woroniecka K, Kemeny HR, Bramall AN, Bernstock JD, Choi BD, Sampson JH. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. Expert Review of Clinical Pharmacology. PMID 32862726 DOI: 10.1080/17512433.2020.1817737  0.01
2020 Hotchkiss KM, Sampson JH. Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. Journal of Neuro-Oncology. PMID 32813186 DOI: 10.1007/s11060-020-03598-2  1
2020 Gedeon PC, Streicker MA, Schaller TH, Archer GE, Jokinen MP, Sampson JH. GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody. Plos One. 15: e0236374. PMID 32735564 DOI: 10.1371/journal.pone.0236374  1
2020 Batich KA, Mitchell DA, Healy P, Herndon JE, Sampson JH. Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32719000 DOI: 10.1158/1078-0432.CCR-20-1082  1
2020 Khasraw M, Reardon DA, Weller M, Sampson JH. PD-1 inhibitors: Do they have a future in the treatment of glioblastoma? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32527943 DOI: 10.1158/1078-0432.CCR-20-1135  1
2020 Wu Y, Kelly SH, Sanchez-Perez L, Sampson JH, Collier JH. Comparative study of α-helical and β-sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes. Biomaterials Science. PMID 32452474 DOI: 10.1039/d0bm00521e  1
2020 Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, ... Sampson J, et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. Jama Oncology. PMID 32437507 DOI: 10.1001/Jamaoncol.2020.1024  1
2020 Schaller TH, Snyder DJ, Spasojevic I, Gedeon PC, Sanchez-Perez L, Sampson JH. First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach. Journal For Immunotherapy of Cancer. 8. PMID 32273346 DOI: 10.1136/jitc-2019-000213  1
2020 Reardon DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM, Cruickshank S, Vitale L, ... Sampson JH, et al. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32034072 DOI: 10.1158/1078-0432.Ccr-18-1140  1
2020 Shen SH, Woroniecka K, Barbour AB, Fecci PE, Sanchez-Perez L, Sampson JH. Checkpoint inhibition and CAR T cells for the Treatment of Glioblastoma. Expert Opinion On Biological Therapy. PMID 32027536 DOI: 10.1080/14712598.2020.1727436  1
2020 Moravan MJ, Fecci PE, Anders CK, Clarke JM, Salama AKS, Adamson JD, Floyd SR, Torok JA, Salama JK, Sampson JH, Sperduto PW, Kirkpatrick JP. Current multidisciplinary management of brain metastases. Cancer. PMID 31971613 DOI: 10.1002/Cncr.32714  1
2019 Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nature Reviews. Cancer. PMID 31806885 DOI: 10.1038/s41568-019-0224-7  1
2019 Huang MN, Nicholson LT, Batich KA, Swartz AM, Kopin D, Wellford S, Prabhakar VK, Woroniecka K, Nair SK, Fecci PE, Sampson JH, Gunn MD. Antigen-loaded monocyte administration induces potent therapeutic anti-tumor T cell responses. The Journal of Clinical Investigation. PMID 31661470 DOI: 10.1172/JCI128267  1
2019 Fecci PE, Sampson JH. The current state of immunotherapy for gliomas: an eye toward the future. Journal of Neurosurgery. 131: 657-666. PMID 31473668 DOI: 10.3171/2019.5.JNS181762  1
2019 Schaller TH, Foster MW, Thompson JW, Spasojevic I, Normantaite D, Moseley MA, Sanchez-Perez L, Sampson JH. Pharmacokinetic analysis of a novel human EGFRvIII:CD3 bispecific antibody in plasma and whole blood using a high-resolution targeted mass spectrometry approach. Journal of Proteome Research. PMID 31267741 DOI: 10.1021/acs.jproteome.9b00145  1
2019 Fecci PE, Champion CD, Hoj J, McKernan C, Goodwin CR, Kirkpatrick J, Anders CK, Pendergast AM, Sampson JH. The Evolving Modern Management of Brain Metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31213459 DOI: 10.1158/1078-0432.Ccr-18-1624  1
2019 Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, ... Sampson JH, et al. Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'. Nature Reviews. Clinical Oncology. PMID 31150022 DOI: 10.1038/S41571-019-0236-Y  1
2019 Desjardins A, Herndon JE, McSherry F, Ravelo A, Lipp ES, Healy P, Peters KB, Sampson JH, Randazzo D, Sommer N, Friedman AH, Friedman HS. Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice. Health Science Reports. 2: e114. PMID 31049419 DOI: 10.1002/hsr2.114  1
2019 Hansen LJ, Sun R, Yang R, Singh SX, Chen LH, Pirozzi CJ, Moure CJ, Hemphill C, Carpenter AB, Healy P, Ruger RC, Chen CJ, Greer PK, Zhao F, Spasojevic I, ... Sampson JH, et al. MTAP loss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation. Cancer Research. PMID 31040154 DOI: 10.1158/0008-5472.Can-18-1010  1
2019 Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain Tumor Micro-environment and Host State - Implications for Immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30804019 DOI: 10.1158/1078-0432.Ccr-18-1627  1
2019 Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, ... Sampson JH, et al. Challenges to curing primary brain tumours. Nature Reviews. Clinical Oncology. PMID 30733593 DOI: 10.1038/S41571-019-0177-5  1
2019 Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, ... ... Sampson JH, et al. Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nature Medicine. PMID 30670876 DOI: 10.1038/s41591-019-0355-0  1
2019 Randazzo D, Achrol A, Aghi MK, Bexon M, Brem S, Brenner AJ, Butowski NA, Chandhasin C, Chowdhary SA, Coello M, Floyd J, Kesari S, Merchant F, Merchant N, Vogelbaum MA, ... ... Sampson JH, et al. MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma. Journal of Clinical Oncology. 37: 2039-2039. DOI: 10.1200/Jco.2019.37.15_Suppl.2039  1
2019 Weller M, Reardon D, Brandes A, Sampson J, Mulholland P, Wick A, Baehring J, Ahluwalia M, Roth P, Bähr O, Phuphanich S, Sepulveda J, Souza Pd, Sahebjam S, Potter V, et al. Atim-47. Nivolumab Vs Bevacizumab In Patients With Recurrent Glioblastoma: Exploratory Analysis Of Mgmt Methylation Status And Baseline Corticosteroid Use Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.045  1
2019 Sampson J, Achrol AS, Aghi M, Bankiewicz K, Brem S, Brenner A, Butowski N, Chandhasin C, Chowdhary S, Coello M, Floyd JR, Kesari S, Merchant F, Merchant N, Randazzo D, et al. Atim-30. Combating Recurrent Glioblastoma With Mdna55, An Interleukin-4 Receptor Targeted Immunotherapy, Through Mri-Guided Convective Delivery Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.029  1
2018 Congdon KL, Sanchez-Perez LA, Sampson JH. Effective Effectors: How T cells Access and Infiltrate the Central nervous System. Pharmacology & Therapeutics. PMID 30557632 DOI: 10.1016/J.Pharmthera.2018.12.007  1
2018 Riccione KA, He LZ, Fecci PE, Norberg PK, Suryadevara CM, Swartz A, Healy P, Reap E, Keler T, Li QJ, Congdon KL, Sanchez-Perez L, Sampson JH. CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response. Oncoimmunology. 7: e1502904. PMID 30524899 DOI: 10.1080/2162402X.2018.1502904  1
2018 Choi BD, Maus MV, June CH, Sampson JH. ----Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30446589 DOI: 10.1158/1078-0432.Ccr-18-1625  1
2018 Suryadevara CM, Desai R, Farber SH, Choi BD, Swartz AM, Shen SH, Gedeon PC, Snyder DJ, Herndon JE, Healy P, Reap EA, Archer GE, Fecci PE, Sampson JH, Sanchez-Perez L. Preventing Lck activation in CAR T cells confers Treg resistance but requires 4-1BB signaling for them to persist and treat solid tumors in non-lymphodepleted hosts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30425092 DOI: 10.1158/1078-0432.CCR-18-1211  1
2018 Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, ... Sampson JH, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nature Medicine. PMID 30104766 DOI: 10.1038/s41591-018-0135-2  1
2018 Atik AF, Suryadevara CM, Schweller RM, West JL, Healy P, Herndon Ii JE, Congdon KL, Sanchez-Perez L, McLendon RE, Archer GE, Fecci P, Sampson JH. Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. PMID 30041899 DOI: 10.1016/J.Jocn.2018.06.005  1
2018 Desjardins A, Gromeier M, Herndon JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. The New England Journal of Medicine. PMID 29943666 DOI: 10.1056/Nejmoa1716435  1
2018 Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, Chongsathidkiet P, Gedeon PC, Elsamadicy AA, Snyder DJ, Herndon JE, Healy P, Archer GE, Choi BD, Fecci PE, Sampson JH, et al. Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. Oncoimmunology. 7: e1434464. PMID 29872570 DOI: 10.1080/2162402X.2018.1434464  1
2018 Swartz AM, Reap E, Norberg P, Schmittling R, Janetzki S, Sanchez-Perez L, Sampson JH. A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis. Journal of Immunological Methods. PMID 29859231 DOI: 10.1016/j.jim.2018.05.015  1
2018 Colman H, Westphal M, Sampson JH. Introduction. Update on adult neuro-oncology. Neurosurgical Focus. 44: E1. PMID 29852765 DOI: 10.3171/2018.3.FOCUS18149  0.04
2018 Gedeon PC, Schaller TH, Chitneni SK, Choi BD, Kuan CT, Suryadevara CM, Snyder DJ, Schmittling RJ, Szafranski SE, Cui X, Healy P, Herndon JE, McLendon RE, Keir ST, Archer GE, ... ... Sampson JH, et al. A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29703821 DOI: 10.1158/1078-0432.Ccr-17-0126  1
2018 Congdon KL, Sanchez-Perez LA, Sampson JH. Abstract CN02-02: Immunotherapy for central nervous system cancers Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Cn02-02  1
2018 Salgado M, Schaller T, Gedeon P, Snyder D, Archer G, Sanchez-Perez L, Sampson J. Ddis-02. Novel Bispecific Activator Of Macrophages For The Treatment Of Glioblastoma Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.281  1
2018 Achrol A, Bexon M, Bankiewicz K, Brenner AJ, Butowski N, Kesari S, Merchant F, Merchant R, Randazzo D, Vogelbaum M, Zabek M, Sampson J. Atim-05. Intratumoral Delivery Of Mdna55, An Interleukin-4 Receptor Targeted Immunotherapy, By Mri-Guided Convective Delivery For The Treatment Of Recurrent Glioblastoma Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.002  1
2018 Bexon MF, Achrol A, Bankiewicz K, Brenner A, Butowski N, Kesari S, Merchant F, Merchant R, Randazzo D, Vogelbaum M, Zabek M, Sampson J. Understanding biological activity, tumor response and pseudoprogression in a phase-IIb study of MDNA55 in adults with recurrent or progressive glioblastoma (GB). Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy273.368  1
2017 Ewend MG, Friedman AH, Sampson JH. In Memoriam: Robert H. Wilkins, MD, 1934 to 2017. Neurosurgery. 81: 6-8. PMID 31895452 DOI: 10.1093/neuros/nyx283  1
2017 Wu Y, Norberg PK, Reap EA, Congdon KL, Fries CN, Kelly SH, Sampson JH, Conticello VP, Collier JH. A Supramolecular Vaccine Platform Based on α-Helical Peptide Nanofibers. Acs Biomaterials Science & Engineering. 3: 3128-3132. PMID 30740520 DOI: 10.1021/Acsbiomaterials.7B00561  1
2017 Elsamadicy AA, Sergesketter A, Sampson JH, Gottfried ON. Institutional Review of Mortality in 5434 Consecutive Neurosurgery Patients: Are We Improving? Neurosurgery. PMID 29300938 DOI: 10.1093/neuros/nyx603  1
2017 Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, ... ... Sampson JH, et al. Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply. The Lancet. Oncology. 18: e709-e710. PMID 29208433 DOI: 10.1016/S1470-2045(17)30856-2  1
2017 Limon D, McSherry F, Herndon J, Sampson J, Fecci P, Adamson J, Wang Z, Yin FF, Floyd S, Kirkpatrick J, Kim GJ. Single fraction stereotactic radiosurgery for multiple brain metastases. Advances in Radiation Oncology. 2: 555-563. PMID 29204522 DOI: 10.1016/J.Adro.2017.09.002  1
2017 Reap E, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, Norberg PK, Herndon JE, Healy P, Congdon KL, Gedeon PC, Campbell OC, Swartz AM, Riccione KA, Yi JS, ... ... Sampson JH, et al. Dendritic cells enhance polyfunctionality of adoptively transferred T cells which target cytomegalovirus in glioblastoma. Cancer Research. PMID 29093005 DOI: 10.1158/0008-5472.Can-17-0469  1
2017 Sampson JH, Haglund MM, Friedman AH, Ewend MG. Obituary. Robert H. Wilkins, MD, 1934-2017. Journal of Neurosurgery. 1-2. PMID 29027856 DOI: 10.3171/2017.6.JNS171416  1
2017 Schaller TH, Batich KA, Suryadevara CM, Desai R, Sampson JH. Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. Expert Review of Clinical Immunology. PMID 28965431 DOI: 10.1080/1744666X.2017.1384313  1
2017 Ewend MG, Friedman AH, Sampson JH. In Memoriam: Robert H. Wilkins, MD, 1934 to 2017. Neurosurgery. 81: 6-8. PMID 28873999 DOI: 10.1093/neuros/nyx283  1
2017 Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, ... ... Sampson JH, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. The Lancet. Oncology. PMID 28844499 DOI: 10.1016/S1470-2045(17)30517-X  1
2017 Sankey EW, Butler E, Sampson JH. Accuracy of Novel CT-guided Frameless Stereotactic Drilling and Catheter System in Human Cadavers. World Neurosurgery. PMID 28754645 DOI: 10.1016/j.wneu.2017.07.098  0.01
2017 Sampson JH, Maus MV, June CH. Immunotherapy for Brain Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017728089. PMID 28640704 DOI: 10.1200/Jco.2017.72.8089  1
2017 Weller M, Roth P, Preusser M, Wick W, Reardon DA, Platten M, Sampson JH. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nature Reviews. Neurology. PMID 28497804 DOI: 10.1038/Nrneurol.2017.64  1
2017 Narloch JL, Farber SH, Sammons S, McSherry F, Herndon JE, Hoang JK, Yin FF, Sampson JH, Fecci PE, Blackwell KL, Kirkpatrick JP, Kim GJ. Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis. Neuro-Oncology. PMID 28472527 DOI: 10.1093/Neuonc/Nox090  1
2017 Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, Norberg P, Xie W, Herndon JE, Healy P, McLendon RE, Friedman AH, Friedman HS, Bigner D, Vlahovic G, ... ... Sampson JH, et al. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 1898-1909. PMID 28411277 DOI: 10.1158/1078-0432.Ccr-16-2057  1
2017 Reardon DA, Wen PY, Wucherpfennig KW, Sampson JH. Immunomodulation for glioblastoma. Current Opinion in Neurology. PMID 28368867 DOI: 10.1097/Wco.0000000000000451  1
2017 Elsamadicy AA, Chongsathidkiet P, Desai R, Woroniecka K, Farber SH, Fecci PE, Sampson JH. Prospect of rindopepimut in the treatment of glioblastoma. Expert Opinion On Biological Therapy. 17: 507-513. PMID 28274144 DOI: 10.1080/14712598.2017.1299705  1
2017 Sayour EJ, De Leon G, Pham C, Grippin A, Kemeny H, Chua J, Huang J, Sampson JH, Sanchez-Perez L, Flores C, Mitchell DA. Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles. Oncoimmunology. 6: e1256527. PMID 28197373 DOI: 10.1080/2162402X.2016.1256527  1
2017 Aliabadi H, Nikpour AM, Yoo DS, Herndon JEI, Sampson JH, Kirkpatrick JP. Pre-operative stereotactic radiosurgery treatment is preferred to post-operative treatment for smaller solitary brain metastases Chinese Journal of Neurosurgery. 3: 1-8. DOI: 10.1186/S41016-017-0092-5  1
2017 Bankiewicz K, Achrol A, Aghi M, Bexon M, Brenner A, Butowski N, Elder B, Floyd J, Lonser R, Merchant F, Rosemina M, Patel TR, Randazzo D, Souweidane M, Vogelbaum M, ... Sampson J, et al. Atim-16. Mri-Guided Convective Delivery Of Mdna55, An Interleukin-4 Receptor Targeted Immunotherapy For The Treatment Of Recurrent Glioblastoma Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.111  1
2017 Reardon DA, Omuro A, Brandes AA, Rieger J, Wick A, Sepulveda J, Phuphanich S, Souza Pd, Ahluwalia MS, Lim M, Vlahovic G, Sampson J. OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143 Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox036.071  1
2016 Suryadevara CM, Desai R, Farber SH, Gedeon PC, Swartz A, Snyder D, Herndon J, Healy P, Choi BD, Fecci PE, Sanchez-Perez L, Sampson JH. 369 Chimeric Antigen Receptors Deficient in Lck Signaling Require 4-1BB Costimulation to Expand in Vivo, Resist Regulatory T-Cell Suppression, and Treat Solid Tumors in Immune-Intact Hosts. Neurosurgery. 63: 209-210. PMID 28175613 DOI: 10.1227/01.neu.0000489857.70440.98  1
2016 Sampson JH. Advances in Immunotherapy: Abhijit Guha Award Presentation. Neurosurgery. 63: 85-87. PMID 28175339 DOI: 10.1227/NEU.0000000000001286  0.01
2016 Farber SH, Elsamadicy AA, Atik F, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH. The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opinion On Drug Safety. PMID 27989218 DOI: 10.1080/14740338.2017.1273898  1
2016 Thompson EM, Gururangan S, Grant G, Mitchell D, Sampson JH. The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial. Journal of Neuro-Oncology. PMID 27864705 DOI: 10.1007/S11060-016-2338-Z  1
2016 Limon D, Kim GJ, McSherry F, Herndon J, Fecci PE, Adamson J, Sampson JH, Floyd SR, Wang Z, Vlahovic G, Yin FF, Kirkpatrick JP. Single-Fraction Radiosurgery for 4 or More Brain Metastases. International Journal of Radiation Oncology, Biology, Physics. 96: E84-E85. PMID 27675479 DOI: 10.1016/J.Ijrobp.2016.06.804  1
2016 Kent CL, Mowery YM, Wright AO, Kim GJ, Desjardins A, Peters KB, Vlahovic G, Friedman HS, Cummings TJ, McLendon RE, Friedman AH, Sampson JH, Kirkpatrick JP. Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With Radiation Therapy: A Single-Institution Retrospective Analysis. International Journal of Radiation Oncology, Biology, Physics. 96: E83-E84. PMID 27675478 DOI: 10.1016/J.Ijrobp.2016.06.802  1
2016 Suryadevara CM, Riccione KA, Sampson JH. Immunotherapy gone viral: Bortezomib and oHSV enhance antitumor NK cell activity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27521450 DOI: 10.1158/1078-0432.CCR-16-1666  1
2016 Schaller TH, Sampson JH. Advances and challenges: dendritic cell vaccination strategies for glioblastoma. Expert Review of Vaccines. PMID 27500911 DOI: 10.1080/14760584.2016.1218762  1
2016 Raghavan R, Brady ML, Sampson JH. Delivering therapy to target: improving the odds for successful drug development. Therapeutic Delivery. 7: 457-81. PMID 27403630 DOI: 10.4155/tde-2016-0016  1
2016 Suryadevara CM, Desai R, Farber SH, Gedeon PC, Swartz A, Snyder D, Herndon J, Healy P, Choi BD, Fecci PE, Sanchez-Perez L, Sampson JH. 369 Chimeric Antigen Receptors Deficient in Lck Signaling Require 4-1BB Costimulation to Expand in Vivo, Resist Regulatory T-Cell Suppression, and Treat Solid Tumors in Immune-Intact Hosts. Neurosurgery. 63: 209-210. PMID 27399566 DOI: 10.1227/01.neu.0000489857.70440.98  1
2016 Sampson JH. Advances in Immunotherapy: Abhijit Guha Award Presentation. Neurosurgery. 63: 85-7. PMID 27399370 DOI: 10.1227/NEU.0000000000001286  0.01
2016 Li F, Liu X, Sampson JH, Bigner DD, Li CY. Rapid reprogramming of primary human astrocytes into potent tumor initiating cells with defined genetic factors. Cancer Research. PMID 27364552 DOI: 10.1158/0008-5472.Can-16-0171  1
2016 Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH. Emerging immunotherapies for glioblastoma. Expert Opinion On Emerging Drugs. 21: 133-145. PMID 27223671 DOI: 10.1080/14728214.2016.1186643  1
2016 Batich KA, Swartz AM, Sampson JH. Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy. Methods in Molecular Biology (Clifton, N.J.). 1403: 819-38. PMID 27076169 DOI: 10.1007/978-1-4939-3387-7_47  1
2016 Saraswathula A, Reap EA, Choi BD, Schmittling RJ, Norberg PK, Sayour EJ, Herndon JE, Healy P, Congdon KL, Archer GE, Sanchez-Perez L, Sampson JH. Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunology, Immunotherapy : Cii. PMID 26759007 DOI: 10.1007/S00262-015-1784-3  1
2016 Weller M, Butowski N, Tran D, Recht L, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust S, Iwamoto F, Drappatz J, O’Rourke D, Wong M, Finocchiaro G, Perry J, ... Sampson J, et al. ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.068  1
2015 Sampson JH. Alternating Electric Fields for the Treatment of Glioblastoma. Jama. 314: 2511-3. PMID 26670969 DOI: 10.1001/jama.2015.16701  1
2015 Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, ... ... Sampson JH, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. The Lancet. Oncology. 16: e534-42. PMID 26545842 DOI: 10.1016/S1470-2045(15)00088-1  1
2015 Sampson JH, Mitchell DA. Vaccination strategies for neuro-oncology. Neuro-Oncology. 17: vii15-vii25. PMID 26516221 DOI: 10.1093/neuonc/nov159  1
2015 Murray DD, Suzuki K, Law M, Trebicka J, Neuhaus J, Wentworth D, Johnson M, Vjecha MJ, Kelleher AD, Emery S. Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. Plos One. 10: e0139981. PMID 26465293 DOI: 10.1371/Journal.Pone.0139981  1
2015 Pham CD, Flores C, Yang C, Pinheiro EM, Yearley JH, Sayour E, Pei Y, Moore C, McLendon RE, Huang J, Sampson JH, Wechsler-Reya RJ, Mitchell DA. Differential immune microenvironments and response to immune checkpoint blockade amongst molecular subtypes of murine medulloblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26405194 DOI: 10.1158/1078-0432.Ccr-15-0713  1
2015 Nair SK, Driscoll T, Boczkowski D, Schmittling R, Reynolds R, Johnson LA, Grant G, Fuchs H, Bigner DD, Sampson JH, Gururangan S, Mitchell DA. Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. Journal of Neuro-Oncology. PMID 26311248 DOI: 10.1007/S11060-015-1890-2  1
2015 Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nature Reviews. Neurology. 11: 504-14. PMID 26260659 DOI: 10.1038/Nrneurol.2015.139  1
2015 Babu R, Sampson JH. Editorial: Patient validation of retrospective data. Journal of Neurosurgery. 123: 969-71. PMID 26252462 DOI: 10.3171/2015.3.JNS142959  1
2015 Reardon DA, Schuster JM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Desjardins A, Ashby LS, Duic JP, Mrugala MM, Werner A, Hawthorne T, He Y, ... ... Sampson JH, et al. 107 ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma. Neurosurgery. 62: 198-199. PMID 26181953 DOI: 10.1227/01.Neu.0000467069.86811.3F  1
2015 Suryadevara CM, Gedeon PC, Sanchez-Perez L, Verla T, Alvarez-Breckenridge C, Choi BD, Fecci PE, Sampson JH. Are BiTEs the "missing link" in cancer therapy? Oncoimmunology. 4: e1008339. PMID 26155413 DOI: 10.1080/2162402X.2015.1008339  1
2015 Choi BD, Fecci PE, Sampson JH. Editorial: Not everything that matters can be measured and not everything that can be measured matters. Journal of Neurosurgery. 123: 543-4. PMID 26115465 DOI: 10.3171/2015.2.JNS142977  1
2015 Vlahovic G, Fecci PE, Reardon D, Sampson JH. Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. Neuro-Oncology. 17: 1043-5. PMID 25964311 DOI: 10.1093/neuonc/nov071  1
2015 Flores C, Pham C, Snyder D, Yang S, Sanchez-Perez L, Sayour E, Cui X, Kemeny H, Friedman H, Bigner DD, Sampson J, Mitchell DA. Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. Oncoimmunology. 4: e994374. PMID 25949916 DOI: 10.4161/2162402X.2014.994374  1
2015 Lin R, Sampson JH, Li QJ, Zhu B. miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor microenvironment. Oncoimmunology. 4: e990803. PMID 25949909 DOI: 10.4161/2162402X.2014.990803  1
2015 Fecci PE, Babu R, Adamson DC, Sampson JH. Editorial: Turning fluorescence into black and white. Journal of Neurosurgery. 122: 1356-9. PMID 25839932 DOI: 10.3171/2014.10.JNS141788  1
2015 Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE, Coan A, McLendon RE, ... ... Sampson JH, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 519: 366-9. PMID 25762141 DOI: 10.1038/Nature14320  1
2015 Riccione K, Suryadevara CM, Snyder D, Cui X, Sampson JH, Sanchez-Perez L. Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care. Journal of Visualized Experiments : Jove. PMID 25741761 DOI: 10.3791/52397  1
2015 Suryadevara CM, Verla T, Sanchez-Perez L, Reap EA, Choi BD, Fecci PE, Sampson JH. Immunotherapy for malignant glioma. Surgical Neurology International. 6: S68-77. PMID 25722935 DOI: 10.4103/2152-7806.151341  1
2015 Brown KE, Chagoya G, Kwatra SG, Yen T, Keir ST, Cooter M, Hoadley KA, Rasheed A, Lipp ES, Mclendon R, Ali-Osman F, Bigner DD, Sampson JH, Kwatra MM. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. Journal of Neurochemistry. 133: 730-8. PMID 25598002 DOI: 10.1111/Jnc.13032  1
2015 Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, ... ... Sampson JH, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro-Oncology. 17: 854-61. PMID 25586468 DOI: 10.1093/Neuonc/Nou348  1
2015 Sayour EJ, McLendon P, McLendon R, De Leon G, Reynolds R, Kresak J, Sampson JH, Mitchell DA. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunology, Immunotherapy : Cii. 64: 419-27. PMID 25555571 DOI: 10.1007/S00262-014-1651-7  1
2015 Swartz AM, Batich KA, Fecci PE, Sampson JH. Peptide vaccines for the treatment of glioblastoma. Journal of Neuro-Oncology. 123: 433-40. PMID 25491947 DOI: 10.1007/s11060-014-1676-y  1
2015 Kirkpatrick JP, Wang Z, Sampson JH, McSherry F, Herndon JE, Allen KJ, Duffy E, Hoang JK, Chang Z, Yoo DS, Kelsey CR, Yin FF. Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 91: 100-8. PMID 25442342 DOI: 10.1016/J.Ijrobp.2014.09.004  1
2015 Mitchell DA, Sayour EJ, Reap E, Schmittling R, DeLeon G, Norberg P, Desjardins A, Friedman AH, Friedman HS, Archer G, Sampson JH. Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. Cancer Immunology Research. 3: 320-5. PMID 25387895 DOI: 10.1158/2326-6066.Cir-14-0100  1
2015 Batich KA, Swartz AM, Sampson JH. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. Expert Opinion On Biological Therapy. 15: 79-94. PMID 25327832 DOI: 10.1517/14712598.2015.972361  1
2015 Reardon DA, Schuster J, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Desjardins A, Ashby LS, Duic JP, Mrugala MM, Werner A, Hawthorne T, He Y, ... ... Sampson JH, et al. ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. Journal of Clinical Oncology. 33: 2009-2009. DOI: 10.1200/Jco.2015.33.15_Suppl.2009  1
2015 Boyle J, McSherry F, Herndon J, Desjardins A, Sampson J, Peters K, Chino J, Allen K, Cabrera A, Kim G, Friedman H, Kirkpatrick J. Rtrb-04Stereotactic Radiosurgery For Recurrent High-Grade Gliomas: Patient Selection And The Role Of Bevacizumab Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov231.04  1
2015 Okada H, Weller M, Huang R, Finocchiaro G, Gilbert M, Wick W, Ellingson B, Hashimoto N, Pollack I, Brandes A, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope W, ... Sampson J, et al. NIMG-56IMMUNOTHERAPY RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (iRANO): A REPORT OF THE RANO WORKING GROUP Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov225.56  1
2015 Reardon DA, Desjardins A, Schuster J, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM, Werner A, Vitale L, He Y, ... ... Sampson JH, et al. IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov218.08  1
2015 Weant M, Dunn-Pirio A, Peters K, Vlahovic G, Randazzo D, Herndon J, Healy P, Threatt S, Sampson J, Friedman A, Friedman H, Desjardins A. Atct-13Bevacizumab, Radiation Therapy (Rt) And Temozolomide Followed By Bevacizumab And Temozolomide With Continuation Of Bevacizumab Beyond Progression: A Phase Ii Trial Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov206.13  1
2015 Nair SK, Driscoll T, Boczkowski D, Schmittling R, Reynolds R, Johnson LA, Grant G, Fuchs H, Bigner DD, Sampson JH, Gururangan S, Mitchell DA. Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma Journal of Neuro-Oncology. DOI: 10.1007/s11060-015-1890-2  1
2014 Oh DS, Vredenburgh JA, Reardon DA, Prosnitz LR, Gockerman JP, Sampson JH, Kelsey CR, Kirkpatrick JP. Low-dose whole brain radiotherapy combined with radiosurgery for primary CNS lymphoma achieving partial response to induction methotrexate-based chemotherapy. Journal of Radiosurgery and Sbrt. 3: 37-42. PMID 29296383  1
2014 Johnson LA, Sanchez-Perez L, Suryadevara CM, Sampson JH. Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence. Oncoimmunology. 3: e944059. PMID 25610729 DOI: 10.4161/21624011.2014.944059  1
2014 Sanchez-Perez L, Suryadevara CM, Choi BD, Reap EA, Sampson JH. Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. Oncoimmunology. 3: e944054. PMID 25610727 DOI: 10.4161/21624011.2014.944054  1
2014 Fecci PE, Heimberger AB, Sampson JH. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5620-9. PMID 25398845 DOI: 10.1158/1078-0432.CCR-14-0832  1
2014 Lin R, Chen L, Chen G, Hu C, Jiang S, Sevilla J, Wan Y, Sampson JH, Zhu B, Li QJ. Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. The Journal of Clinical Investigation. 124: 5352-67. PMID 25347474 DOI: 10.1172/Jci76561  1
2014 Congdon KL, Gedeon PC, Suryadevara CM, Caruso HG, Cooper LJ, Heimberger AB, Sampson JH. Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro-Oncology. 16: viii20-5. PMID 25342601 DOI: 10.1093/Neuonc/Nou236  1
2014 Kirkpatrick JP, Sampson JH. Recurrent malignant gliomas. Seminars in Radiation Oncology. 24: 289-98. PMID 25219814 DOI: 10.1016/j.semradonc.2014.06.006  1
2014 Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, Fritsch EF, Curry WT, Sampson JH, Dranoff G. Immunotherapy advances for glioblastoma. Neuro-Oncology. 16: 1441-58. PMID 25190673 DOI: 10.1093/Neuonc/Nou212  1
2014 Swartz AM, Li QJ, Sampson JH. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. Immunotherapy. 6: 679-90. PMID 25186601 DOI: 10.2217/Imt.14.21  1
2014 Gedeon PC, Riccione KA, Fecci PE, Sampson JH. Antibody-based immunotherapy for malignant glioma. Seminars in Oncology. 41: 496-510. PMID 25173142 DOI: 10.1053/j.seminoncol.2014.06.004  1
2014 Batich KA, Sampson JH. Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. Expert Opinion On Pharmacotherapy. 15: 2047-61. PMID 25139628 DOI: 10.1517/14656566.2014.947266  1
2014 Nair SK, Sampson JH, Mitchell DA. Immunological targeting of cytomegalovirus for glioblastoma therapy. Oncoimmunology. 3: e29289. PMID 25101224 DOI: 10.4161/onci.29289  1
2014 Kanaly CW, Mehta AI, Ding D, Hoang JK, Kranz PG, Herndon JE, Coan A, Crocker I, Waller AF, Friedman AH, Reardon DA, Sampson JH. A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma. Journal of Neurosurgery. 121: 536-42. PMID 25036205 DOI: 10.3171/2014.4.JNS121952  1
2014 Brown MC, Dobrikova EY, Dobrikov MI, Walton RW, Gemberling SL, Nair SK, Desjardins A, Sampson JH, Friedman HS, Friedman AH, Tyler DS, Bigner DD, Gromeier M. Oncolytic polio virotherapy of cancer. Cancer. 120: 3277-86. PMID 24939611 DOI: 10.1002/Cncr.28862  1
2014 Babu R, Thomas S, Hazzard MA, Friedman AH, Sampson JH, Adamson C, Zomorodi AR, Haglund MM, Patil CG, Boakye M, Lad SP. Worse outcomes for patients undergoing brain tumor and cerebrovascular procedures following the ACGME resident duty-hour restrictions. Journal of Neurosurgery. 121: 262-76. PMID 24926647 DOI: 10.3171/2014.5.Jns1314  1
2014 Choi BD, DeLong MR, Sampson JH. Response. Journal of Neurosurgery. 120: 728-9. PMID 24724172 DOI: 10.3171/2013.8.JNS131489  1
2014 Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, Sayour EJ, McLendon R, Herndon JE, Healy P, Archer GE, Bigner DD, Johnson LA, Sampson JH. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. Plos One. 9: e94281. PMID 24722266 DOI: 10.1371/Journal.Pone.0094281  1
2014 Nair SK, De Leon G, Boczkowski D, Schmittling R, Xie W, Staats J, Liu R, Johnson LA, Weinhold K, Archer GE, Sampson JH, Mitchell DA. Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2684-94. PMID 24658154 DOI: 10.1158/1078-0432.CCR-13-3268  1
2014 Sampson JH, Barker FG. Methodology and reporting of meta-analyses in the neurosurgical literature. Journal of Neurosurgery. 120: 791-4. PMID 24460491 DOI: 10.3171/2013.10.JNS13724  1
2014 Sampson JH, Vlahovic G. Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial". Neuro-Oncology. 16: 169-70. PMID 24443362 DOI: 10.1093/neuonc/not311  1
2014 Choi BD, DeLong MR, DeLong DM, Friedman AH, Sampson JH. Impact of PhD training on scholarship in a neurosurgical career. Journal of Neurosurgery. 120: 730-5. PMID 24359004 DOI: 10.3171/2013.11.JNS122370  1
2014 Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, Herndon JE, Kuan CT, Morgan RA, Rosenberg SA, Johnson LA. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 972-84. PMID 24352643 DOI: 10.1158/1078-0432.CCR-13-0709  1
2014 Sampson JH, Lad SP, Herndon JE, Starke RM, Kondziolka D. SEER insights. Journal of Neurosurgery. 120: 297-8. PMID 24286150 DOI: 10.3171/2013.6.Jns13993  1
2014 Choi BD, Suryadevara CM, Gedeon PC, Herndon JE, Sanchez-Perez L, Bigner DD, Sampson JH. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 21: 189-90. PMID 24054399 DOI: 10.1016/J.Jocn.2013.03.012  1
2014 Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, Leon GD, Sayour EJ, McLendon R, Herndon JE, Healy P, Archer GE, Bigner DD, Johnson LA, Sampson JH. D-270MG FLuc/GFP xenograft is highly invasive in NSG mice. Plos One. DOI: 10.1371/Journal.Pone.0094281.G001  1
2014 Sampson JH, Vlahovic G, Desjardins A, Friedman HS, Baehring JM, Hafler D, Rollin L, Coric V, Perez SN, Reardon DA. Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps2101  1
2014 Friedman HS, Herndon JE, McSherry F, Ravelo A, Lipp ES, Healy P, Peters KB, Ranjan T, Vlahovic G, Watts J, Sampson JH, Friedman AH, Desjardins A. Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts) treated on bevacizumab (BEV) in clinical practice. Journal of Clinical Oncology. 32: 2082-2082. DOI: 10.1200/Jco.2014.32.15_Suppl.2082  1
2014 Desjardins A, Sampson JH, Peters KB, Ranjan T, Vlahovic G, Threatt S, Herndon JE, Boulton S, Lally-Goss D, McSherry F, Friedman A, Friedman HS, Bigner DD, Gromeier M. Abstract CT416: Intratumoral administration of an Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in recurrent glioblastoma (GBM): Preliminary results of the Phase I clinical trial Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct416  1
2014 Kang J, Desjardins A, Healy P, Herndon J, Lipp E, Peters K, Vlahovic G, Sampson J, Friedman H, Friedman A, Adamson C. Sm-02Levetiracetam Usage In Post-Operative Seizure Management In Malignant Glioma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou277.2  1
2014 Reardon D, Schuster J, Tran D, Fink K, Nabors L, Li G, Lukas R, Desjardins A, Ashby L, Duic JP, Aneiro L, Hawthorne T, Green J, Yellin M, Davis T, Sampson J, et al. IT-30ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou258.28  1
2014 Kirkpatrick J, Wang Z, Sampson J, McSherry F, Herndon J, Allen K, Duffy E, Chang Z, Hoang J, Kelsey C, Yoo D, Cabrera A, Yin F. Bm-17Final Results Of A Randomized Trial To Identify The Optimal Planning Target Volume In Image-Guided Stereotactic Radiosurgery Of Brain Metastases Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou240.17  1
2014 Ghiaseddin A, Dunn-Pirio A, Peters K, Vlahovic G, Herndon J, Threatt S, Sampson J, Friedman A, Friedman H, Desjardins A. At-22Phase Ii Trial Of Bevacizumab, Radiation Therapy (Rt) And Temozolomide Followed By Bevacizumab And Temozolomide With Continuation Of Bevacizumab Beyond Progression Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.22  1
2014 Desjardins A, Herndon J, McSherry F, Ravelo A, Lipp E, Healy P, Peters K, Vlahovic G, Sampson J, Friedman A, Friedman H. At-20Single Institution Retrospective Review Of Performance Status And Corticosteroid Use In Newly Diagnosed Glioblastoma (Gbm) Patients (Pts) Treated On Bevacizumab (Bev) Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.20  1
2014 Desjardins A, Herndon J, McSherry F, Ravelo A, Lipp E, Healy P, Boulton S, Peters K, Vlahovic G, Sampson J, Friedman A, Friedman H. At-19Single Institution Retrospective Comparison Of Glioblastoma (Gbm) Patients (Pts) Initiated On Bevacizumab (Bev) Before Versus After Recurrence In Clinical Practice Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.19  1
2014 Sampson J, Mitchell DA, Batich KA, Snyder D, Xie W, Reap E, Cui X, Sanchez-Perez L, Archer GE, Nair SK, Gunn MD. RANDOMIZATION OF PATIENTS WITH GLIOBLASTOMA TO VACCINE SITE PRE-CONDITIONING WITH TETANUS-DIPHTHERIA TOXOID SYSTEMICALLY ENHANCES MIGRATION AND THERAPEUTIC EFFECT OF CYTOMEGALOVIRUS PP65-PULSED DENDRITIC CELL VACCINE IN A MIP-1α-DEPENDENT FASHION Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou208.63  1
2013 Gedeon PC, Choi BD, Sampson JH, Bigner DD. Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic. Drugs of the Future. 38: 147-155. PMID 25663738 DOI: 10.1358/Dof.2013.038.03.1933992  1
2013 Choi BD, Gedeon PC, Herndon JE, Archer GE, Reap EA, Sanchez-Perez L, Mitchell DA, Bigner DD, Sampson JH. Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. Cancer Immunology Research. 1: 163. PMID 24570975 DOI: 10.1158/2326-6066.Cir-13-0049  1
2013 Choi BD, Gedeon PC, Sanchez-Perez L, Bigner DD, Sampson JH. Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. Oncoimmunology. 2: e26757. PMID 24475376 DOI: 10.4161/Onci.26757  1
2013 Congdon KL, Sampson JH. Enhanced oncolytic virotherapy through oxidative stress inhibition. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1981-3. PMID 24201213 DOI: 10.1038/Mt.2013.227  1
2013 Yang S, Archer GE, Flores CE, Mitchell DA, Sampson JH. A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. Cancer Immunology, Immunotherapy : Cii. 62: 1649-62. PMID 23982483 DOI: 10.1007/s00262-013-1464-0  1
2013 Dannull J, Haley NR, Archer G, Nair S, Boczkowski D, Harper M, De Rosa N, Pickett N, Mosca PJ, Burchette J, Selim MA, Mitchell DA, Sampson J, Tyler DS, Pruitt SK. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. The Journal of Clinical Investigation. 123: 3135-45. PMID 23934126 DOI: 10.1172/Jci67544  1
2013 Gedeon PC, Choi BD, Hodges TR, Mitchell DA, Bigner DD, Sampson JH. An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Review of Clinical Pharmacology. 6: 375-86. PMID 23927666 DOI: 10.1586/17512433.2013.811806  1
2013 Chandramohan V, Mitchell DA, Johnson LA, Sampson JH, Bigner DD. Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncology (London, England). 9: 977-90. PMID 23837761 DOI: 10.2217/Fon.13.47  1
2013 Choi BD, Gedeon PC, Kuan CT, Sanchez-Perez L, Archer GE, Bigner DD, Sampson JH. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. Journal of Immunological Methods. 395: 14-20. PMID 23806556 DOI: 10.1016/J.Jim.2013.06.003  1
2013 Batich KA, William St Clair E, McLendon RE, Sampson JH. Complete response to steroids in dural inflammatory pseudotumor associated with Still's disease. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 20: 1445-8. PMID 23768965 DOI: 10.1016/J.Jocn.2013.01.009  1
2013 Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, Curry WT, Mitchell DA, Fecci PE, Sampson JH, Dranoff G. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Review of Vaccines. 12: 597-615. PMID 23750791 DOI: 10.1586/Erv.13.41  1
2013 Choi BD, Pastan I, Bigner DD, Sampson JH. A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. Oncoimmunology. 2: e23639. PMID 23734318 DOI: 10.4161/Onci.23639  1
2013 Cabrera AR, Cuneo KC, Desjardins A, Sampson JH, McSherry F, Herndon JE, Peters KB, Allen K, Hoang JK, Chang Z, Craciunescu O, Vredenburgh JJ, Friedman HS, Kirkpatrick JP. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. International Journal of Radiation Oncology, Biology, Physics. 86: 873-9. PMID 23725997 DOI: 10.1016/J.Ijrobp.2013.04.029  1
2013 Babu R, Hatef J, McLendon RE, Cummings TJ, Sampson JH, Friedman AH, Adamson C. Clinicopathological characteristics and treatment of rhabdoid glioblastoma. Journal of Neurosurgery. 119: 412-9. PMID 23641829 DOI: 10.3171/2013.3.Jns121773  1
2013 Kirkpatrick JP, Yin FF, Sampson JH. Radiotherapy and radiosurgery for tumors of the central nervous system. Surgical Oncology Clinics of North America. 22: 445-61. PMID 23622073 DOI: 10.1016/J.Soc.2013.02.008  1
2013 Sanchez-Perez L, Choi BD, Reap EA, Sayour EJ, Norberg P, Schmittling RJ, Archer GE, Herndon JE, Mitchell DA, Heimberger AB, Bigner DD, Sampson JH. BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunology, Immunotherapy : Cii. 62: 983-7. PMID 23591978 DOI: 10.1007/S00262-013-1405-Y  1
2013 Hodges TR, Choi BD, Bigner DD, Yan H, Sampson JH. Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review. Journal of Neurosurgery. 118: 1176-80. PMID 23581583 DOI: 10.3171/2013.3.Jns122282  1
2013 Sanchez-Perez LA, Choi BD, Archer GE, Cui X, Flores C, Johnson LA, Schmittling RJ, Snyder D, Herndon JE, Bigner DD, Mitchell DA, Sampson JH. Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. Plos One. 8: e59082. PMID 23527092 DOI: 10.1371/Journal.Pone.0059082  1
2013 Mehta AI, Babu R, Sharma R, Karikari IO, Grunch BH, Owens TR, Agarwal VJ, Sampson JH, Lad SP, Friedman AH, Kuchibhatla M, Bagley CA, Gottfried ON. Thickness of subcutaneous fat as a risk factor for infection in cervical spine fusion surgery. The Journal of Bone and Joint Surgery. American Volume. 95: 323-8. PMID 23426766 DOI: 10.2106/Jbjs.L.00225  1
2013 Choi BD, Kuan CT, Cai M, Archer GE, Mitchell DA, Gedeon PC, Sanchez-Perez L, Pastan I, Bigner DD, Sampson JH. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proceedings of the National Academy of Sciences of the United States of America. 110: 270-5. PMID 23248284 DOI: 10.1073/Pnas.1219817110  1
2013 Zomorodi A, Herndon JE, Sampson JH. Subarachnoid hemorrhage trials. Journal of Neurosurgery. 118: 1-2; discussion 2. PMID 23039153 DOI: 10.3171/2012.5.JNS12730  0.01
2013 Nonaka Y, Fukushima T, Watanabe K, Friedman AH, Sampson JH, Mcelveen JT, Cunningham CD, Zomorodi AR. Contemporary surgical management of vestibular schwannomas: analysis of complications and lessons learned over the past decade. Neurosurgery. 72: ons103-15; discussio. PMID 23037828 DOI: 10.1227/NEU.0b013e3182752b05  1
2013 Mehta AI, Brufsky AM, Sampson JH. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treatment Reviews. 39: 261-9. PMID 22727691 DOI: 10.1016/j.ctrv.2012.05.006  1
2013 Ambady P, Holdhoff M, Ferrigno C, Grossman S, Anderson MD, Liu D, Conrad C, Penas-Prado M, Gilbert MR, Yung AWK, Groot Jd, Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, ... Sampson J, et al. Neuro/Medical Oncology Neuro-Oncology. 15: 120-120. DOI: 10.1093/Neuonc/Not182  1
2013 Zomorodi A, Nonaka Y, Friedman A, Sampson J, Fukushima T. Surgical Management of Vestibular Schwannomas after Failed Radiation Skull Base Surgery. 74. DOI: 10.1055/S-0033-1336256  1
2013 Kirkpatrick JP, Wang Z, Sampson J, Kelsey C, Allen K, Duffy E, Green S, Cabrera A, Palta M, Yin F. Early Results of a Randomized Trial to Identify an Optimal PTV in Stereotactic Radiosurgery of Brain Metastases International Journal of Radiation Oncology Biology Physics. 87. DOI: 10.1016/J.Ijrobp.2013.06.131  1
2013 Chandramohan V, Mitchell DA, Gromeier M, Sampson JH, Bigner DD. Current immunotherapeutic targets in gliomas Gliomas: Symptoms, Diagnosis and Treatment Options. 287-305.  1
2012 Mehta VA, Sampson JH. The limitations of imaging response criteria. The Lancet. Oncology. 13: 1064-5. PMID 23116995 DOI: 10.1016/S1470-2045(12)70458-8  1
2012 Choi BD, Fecci PE, Sampson JH. Regulatory T cells move in when gliomas say "I Do". Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6086-8. PMID 23052252 DOI: 10.1158/1078-0432.CCR-12-2801  1
2012 Reardon DA, Herndon JE, Peters KB, Desjardins A, Coan A, Lou E, Sumrall AL, Turner S, Lipp ES, Sathornsumetee S, Rich JN, Sampson JH, Friedman AH, Boulton ST, Bigner DD, et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. British Journal of Cancer. 107: 1481-7. PMID 23037712 DOI: 10.1038/Bjc.2012.415  1
2012 Reitman ZJ, Choi BD, Spasojevic I, Bigner DD, Sampson JH, Yan H. Enzyme redesign guided by cancer-derived IDH1 mutations. Nature Chemical Biology. 8: 887-9. PMID 23001033 DOI: 10.1038/Nchembio.1065  1
2012 Sampson JH. Editorial: Convection-enhanced delivery. Journal of Neurosurgery. 117: 1126-7; discussion 1. PMID 22998062 DOI: 10.3171/2012.1.JNS12208  1
2012 Cabrera AR, Cuneo KC, Vredenburgh JJ, Sampson JH, Kirkpatrick JP. Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme. Journal of the National Comprehensive Cancer Network : Jnccn. 10: 695-9. PMID 22679114  1
2012 Cuneo KC, Zagar TM, Brizel DM, Yoo DS, Hoang JK, Chang Z, Wang Z, Yin FF, Das SK, Green S, Ready N, Bhatti MT, Kaylie DM, Becker A, Sampson JH, et al. Stereotactic radiotherapy for malignancies involving the trigeminal and facial nerves. Technology in Cancer Research & Treatment. 11: 221-8. PMID 22468993 DOI: 10.7785/Tcrt.2012.500290  1
2012 Choi BD, Mehta AI, Batich KA, Friedman AH, Sampson JH. The use of motor mapping to aid resection of eloquent gliomas. Neurosurgery Clinics of North America. 23: 215-25, vii. PMID 22440865 DOI: 10.1016/j.nec.2012.01.013  1
2012 Sampson JH, Hoang JK. Resection and survival. Journal of Neurosurgery. 116: 1169-70; discussion . PMID 22424561 DOI: 10.3171/2011.10.JNS111437  1
2012 Reardon DA, Vredenburgh JJ, Desjardins A, Peters KB, Sathornsumetee S, Threatt S, Sampson JH, Herndon JE, Coan A, McSherry F, Rich JN, McLendon RE, Zhang S, Friedman HS. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. Journal of Neuro-Oncology. 108: 499-506. PMID 22407177 DOI: 10.1007/S11060-012-0848-X  1
2012 Chandramohan V, Sampson JH, Pastan I, Bigner DD. Toxin-based targeted therapy for malignant brain tumors. Clinical & Developmental Immunology. 2012: 480429. PMID 22400035 DOI: 10.1155/2012/480429  1
2012 Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA, Desjardins A, Friedman AH, Friedman HS, Herndon JE, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, et al. A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. Plos One. 7: e31046. PMID 22383993 DOI: 10.1371/Journal.Pone.0031046  1
2012 Mehta AI, Choi BD, Ajay D, Raghavan R, Brady M, Friedman AH, Pastan I, Bigner DD, Sampson JH. Convection enhanced delivery of macromolecules for brain tumors. Current Drug Discovery Technologies. 9: 305-10. PMID 22339074 DOI: 10.2174/157016312803305951  1
2012 Ajay D, Sanchez-Perez L, Choi BD, De Leon G, Sampson JH. Immunotherapy with tumor vaccines for the treatment of malignant gliomas. Current Drug Discovery Technologies. 9: 237-55. PMID 22339070  1
2012 Sampson JH, Herndon JE, McLendon RE, Hasselblad V, Asher AL, McGirt MJ, Peterson ED. Clinical data simplified. Journal of Neurosurgery. 116: 346-8; discussion 34. PMID 22054209 DOI: 10.3171/2011.5.Jns11279  1
2012 Desjardins A, Sampson JH. Avastin: more questions than answers. . . Journal of Neurosurgery. 116: 336-40; discussion 3. PMID 22035270 DOI: 10.3171/2011.8.JNS111107  1
2012 Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. Journal of Neuro-Oncology. 107: 155-64. PMID 21986722 DOI: 10.1007/S11060-011-0722-2  1
2012 Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. Journal of Neuro-Oncology. 106: 409-15. PMID 21938530 DOI: 10.1007/S11060-011-0687-1  1
2012 Sampson JH, Bagley CA, Carson BS. Disparities in care. Journal of Neurosurgery. 116: 280-2; discussion 28. PMID 21740120 DOI: 10.3171/2011.5.JNS11410  1
2012 Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, Macdonald DR, Van den Bent MJ, Chang SM. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 70: 234-43; discussion 2. PMID 21593697 DOI: 10.1227/NEU.0b013e318223f5a7  1
2012 Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. International Journal of Radiation Oncology, Biology, Physics. 82: 2018-24. PMID 21489708 DOI: 10.1016/J.Ijrobp.2010.12.074  1
2012 Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Reardon DA, Peters KB, Herndon JE, Marcello J, Bailey L, Threatt S, Sampson J, Friedman A, Friedman HS. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. International Journal of Radiation Oncology, Biology, Physics. 82: 58-66. PMID 21036490 DOI: 10.1016/J.Ijrobp.2010.08.058  1
2012 Desjardins A, Vredenburgh JJ, Peters KB, Threatt S, Herndon JE, Sampson JH, Friedman AH, Friedman HS, Reardon DA. Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure. Journal of Clinical Oncology. 30: 2095-2095. DOI: 10.1200/Jco.2012.30.15_Suppl.2095  1
2012 Vredenburgh JJ, Desjardins A, Peters KB, Reardon DA, Herndon JE, Coan AD, Kirkpatrick J, Bailey L, Threatt S, Sampson JH, Friedman AH, Friedman HS. Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology. 30: 2094-2094. DOI: 10.1200/Jco.2012.30.15_Suppl.2094  1
2012 Friedman HS, Desjardins A, Peters KB, Reardon DA, Kirkpatrick J, Herndon JE, Coan AD, Bailey L, Sampson JH, Friedman AH, Vredenburgh JJ. The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology. 30: 2090-2090. DOI: 10.1200/Jco.2012.30.15_Suppl.2090  1
2012 Furuse M, Miyatake S, Miyata T, Yoritsune E, Kawabata S, Kuroiwa T, Karajannis MA, Fisher MJ, Milla SS, Cohen KJ, Legault G, Wisoff JH, Harter DH, Hartnett E, Merkelson A, ... ... Sampson JH, et al. Clin-Ongoing Clinical Trials Neuro-Oncology. 14. DOI: 10.1093/Neuonc/Nos232  1
2012 Park C-, Kim Y-, Kim JW, Kim TM, Choi SH, Kim YJ, Choi BS, Lee S-, Kim C-, Kim IH, Lee DZ, Kheder A, Forbes M, Craven I, Hadjivassiliou M, ... ... Sampson J, et al. Clin-Neuro/Medical Oncology Neuro-Oncology. 14. DOI: 10.1093/Neuonc/Nos229  1
2012 Lewis S, Vredenburgh J, Desjardins A, Peters K, Green S, Hood R, Yang Y, Sampson J, Wang Z, Kirkpatrick JP. Patterns of Failure as a Function of Clinical Target Volumes in Patients With GBM Treated With Radiation Therapy (RT), Temozolomide, and Bevacizumab International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.694  1
2012 Cuneo KC, Vredenburgh J, Desjardins A, Peters K, Sampson J, Allen K, Chang Z, Duffy E, Peterson B, Kirkpatrick JP. Impact of Concurrent and Adjuvant Bevacizumab on the Risk of Radiation Necrosis Following Radiosurgery for Recurrent Glioma International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.024  1
2011 Cuneo KC, Cabrera AR, Sampson JH, Allen KJ, Vredenburgh JJ, Peters K, Chang Z, Herndon JE, Desjardins A, Reardon DA, Kirkpatrick J. Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2082. PMID 28019873 DOI: 10.1200/jco.2011.29.15_suppl.2082  1
2011 Mehta AI, Choi BD, Raghavan R, Brady M, Friedman AH, Bigner DD, Pastan I, Sampson JH. Imaging of convection enhanced delivery of toxins in humans. Toxins. 3: 201-6. PMID 22069706 DOI: 10.3390/Toxins3030201  1
2011 Mehta AI, Kanaly CW, Friedman AH, Bigner DD, Sampson JH. Monitoring radiographic brain tumor progression. Toxins. 3: 191-200. PMID 22069705 DOI: 10.3390/Toxins3030191  1
2011 Lou E, Turner S, Sumrall A, Reardon DA, Desjardins A, Peters KB, Sampson JH, Friedman HS, Vredenburgh JJ. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e739-42. PMID 21900098 DOI: 10.1200/Jco.2011.36.1865  1
2011 Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, ... Sampson JH, et al. Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 118: 3003-12. PMID 21768296 DOI: 10.1182/Blood-2011-02-334565  1
2011 Sampson JH, Mitchell DA. Is cytomegalovirus a therapeutic target in glioblastoma? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4619-21. PMID 21632859 DOI: 10.1158/1078-0432.CCR-11-0992  1
2011 Sampson JH, Raghavan R, Brady M, Friedman AH, Bigner D. Convection-enhanced delivery. Journal of Neurosurgery. 115: 463-4; discussion 46. PMID 21619413 DOI: 10.3171/2010.11.Jns101801  1
2011 Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Coan A, Threatt S, Friedman AH, Friedman HS. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 117: 5351-8. PMID 21590689 DOI: 10.1002/Cncr.26188  1
2011 Sampson JH, Kaminski TJ, Schulman KA. Our failure to advance new treatments for glioma to market. Journal of Neurosurgery. 115: 245-7; discussion 24. PMID 21568655 DOI: 10.3171/2010.11.JNS101436  1
2011 Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4119-24. PMID 21531816 DOI: 10.1158/1078-0432.Ccr-11-0120  1
2011 Sampson JH, Herndon JE, Friedman AH, Abernethy AP. Epidemiology. Journal of Neurosurgery. 115: 256-7; discussion 25. PMID 21529133 DOI: 10.3171/2011.1.JNS102066  1
2011 Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Jones LW, Kirkpatrick JP, Friedman AH, Vredenburgh JJ, Bigner DD, Friedman HS. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 414-27. PMID 21464146 DOI: 10.6004/Jnccn.2011.0038  1
2011 Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opinion On Biological Therapy. 11: 843-53. PMID 21449821 DOI: 10.1517/14712598.2011.572874  1
2011 Sampson JH, Brady M, Raghavan R, Mehta AI, Friedman AH, Reardon DA, Petry NA, Barboriak DP, Wong TZ, Zalutsky MR, Lally-Goss D, Bigner DD. Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery. 69: 668-76. PMID 21430586 DOI: 10.1227/Neu.0B013E3182181Ba8  1
2011 Leon GD, Mitchell D, Sampson J. A promising cancer vaccine Future Oncology. 7: 331-334. PMID 21417898 DOI: 10.2217/Fon.11.17  1
2011 Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology. 13: 353-61. PMID 21310734 DOI: 10.1093/Neuonc/Noq203  1
2011 Kanaly CW, Ding D, Mehta AI, Waller AF, Crocker I, Desjardins A, Reardon DA, Friedman AH, Bigner DD, Sampson JH. A novel method for volumetric MRI response assessment of enhancing brain tumors. Plos One. 6: e16031. PMID 21298088 DOI: 10.1371/Journal.Pone.0016031  1
2011 Sampson JH, Herndon JE. Resection of vestibular schwannomas. Journal of Neurosurgery. 114: 1216-7; discussion 1. PMID 21250806 DOI: 10.3171/2010.8.JNS10765  1
2011 Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 13: 324-33. PMID 21149254 DOI: 10.1093/Neuonc/Noq157  1
2011 Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro-Oncology. 13: 3-13. PMID 21149252 DOI: 10.1093/neuonc/noq169  1
2011 Buonerba C, Di Lorenzo G, Marinelli A, Federico P, Palmieri G, Imbimbo M, Conti P, Peluso G, De Placido S, Sampson JH. A comprehensive outlook on intracerebral therapy of malignant gliomas. Critical Reviews in Oncology/Hematology. 80: 54-68. PMID 20888252 DOI: 10.1016/j.critrevonc.2010.09.001  1
2011 Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, McLendon R, Herndon JE, Marcello J, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Journal of Neuro-Oncology. 103: 371-9. PMID 20853132 DOI: 10.1007/S11060-010-0403-6  1
2011 Mueller S, Polley MY, Lee B, Kunwar S, Pedain C, Wembacher-Schröder E, Mittermeyer S, Westphal M, Sampson JH, Vogelbaum MA, Croteau D, Chang SM. Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. Journal of Neuro-Oncology. 101: 267-77. PMID 20563833 DOI: 10.1007/s11060-010-0255-0  1
2011 Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 101: 57-66. PMID 20443129 DOI: 10.1007/S11060-010-0217-6  1
2011 Cuneo KC, Cabrera AR, Sampson J, Allen K, Duffy E, Vredenburgh JJ, Peters KB, Chang Z, Desjardins A, Kirkpatrick JP. Concurrent bevacizumab and radiosurgery for recurrent malignant glioma: toxicity results from a prospective pilot study F1000research. 2. DOI: 10.7490/F1000Research.1089492.1  1
2011 Mehta AI, Persson O, Herndon JE, Archer GE, McLendon R, Heimberger AB, Mitchell DA, Bigner DD, Sampson JH. Reply to M.S. Lesniak Journal of Clinical Oncology. 29: 3105-3106. DOI: 10.1200/Jco.2011.35.0256  1
2011 Heimberger AB, Bigner DD, Herndon JE, Sampson JH. Reply to M.C. Chamberlain Journal of Clinical Oncology. 29: e519-e520. DOI: 10.1200/Jco.2010.34.1453  1
2011 Cuneo KC, Cabrera AR, Sampson J, Allen K, Duffy E, Vredenburgh JJ, Peters KB, Chang Z, Desjardins A, Kirkpatrick JP. Bevacizumab and Radiosurgery for Recurrent Malignant Glioma: Toxicity Results from a Prospective Pilot Study International Journal of Radiation Oncology Biology Physics. 81. DOI: 10.1016/J.Ijrobp.2011.06.330  1
2011 Wang Z, Yin F, Chang Z, Sampson J, Kirkpatrick JP. Imaging-Guided Localization for Stereotactic Radiosurgery of Multiple Intracranial Lesions with a Single Isocenter Setup International Journal of Radiation Oncology Biology Physics. 81. DOI: 10.1016/J.Ijrobp.2011.06.1530  1
2011 Mehta AI, Grant GA, Gray L, Sampson JH. Radiographic progression of a Chiari I malformation after minor head trauma: Final increment of obstruction to create pathophysiology Journal of Surgical Radiology. 2: 290-293.  1
2010 Lifson AR, Belloso WH, Davey RT, Duprez D, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson JH, et al. Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. Hiv Clinical Trials. 11: 205-19. PMID 20974576 DOI: 10.1310/Hct1104-205  1
2010 Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4722-9. PMID 20921459 DOI: 10.1200/Jco.2010.28.6963  1
2010 Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro-Oncology. 12: 871-81. PMID 20511192 DOI: 10.1093/Neuonc/Nop054  1
2010 Chong GT, Mukundan S, Kirkpatrick JP, Zomorodi A, Sampson JH, Tariq Bhatti M. Stereotactic radiosurgery in the treatment of a dural carotid-cavernous fistula Journal of Neuro-Ophthalmology. 30: 138-144. PMID 20431489 DOI: 10.1097/WNO.0b013e3181ceb3e3  1
2010 Johnson LA, Sampson JH. Immunotherapy approaches for malignant glioma from 2007 to 2009. Current Neurology and Neuroscience Reports. 10: 259-66. PMID 20424975 DOI: 10.1007/s11910-010-0111-9  1
2010 Tavel JA, Babiker A, Fox L, Gey D, Lopardo G, Markowitz N, Paton N, Wentworth D, Wyman N. Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. Plos One. 5: e9334. PMID 20186278 DOI: 10.1371/Journal.Pone.0009334  1
2010 Ding D, Kanaly CW, Cummings TJ, Herndon JE, Raghavan R, Sampson JH. Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321. Neurological Research. 32: 810-5. PMID 20021739 DOI: 10.1179/174367509X12581069052090  1
2010 Sampson JH, Archer G, Pedain C, Wembacher-Schröder E, Westphal M, Kunwar S, Vogelbaum MA, Coan A, Herndon JE, Raghavan R, Brady ML, Reardon DA, Friedman AH, Friedman HS, Rodríguez-Ponce MI, et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. Journal of Neurosurgery. 113: 301-9. PMID 20020841 DOI: 10.3171/2009.11.Jns091052  1
2010 Aliabadi H, Vredenburgh JJ, Everson RG, Desjardins A, Friedman HS, McLendon RE, Tucci DL, Sampson JH. Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. Journal of Neuro-Oncology. 98: 427-30. PMID 20020179 DOI: 10.1007/S11060-009-0091-2  1
2010 Humphries W, Wei J, Sampson JH, Heimberger AB. The Role of Tregs in Glioma-Mediated Immunosuppression: Potential Target for Intervention Neurosurgery Clinics of North America. 21: 125-137. PMID 19944972 DOI: 10.1016/j.nec.2009.08.012  1
2010 Kanaly CW, Ding D, Heimberger AB, Sampson JH. Clinical Applications of a Peptide-Based Vaccine for Glioblastoma Neurosurgery Clinics of North America. 21: 95-109. PMID 19944970 DOI: 10.1016/j.nec.2009.09.001  1
2010 Ding D, Kanaly CW, Bigner DD, Cummings TJ, Herndon JE, Pastan I, Raghavan R, Sampson JH. Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. Journal of Neuro-Oncology. 98: 1-7. PMID 19898744 DOI: 10.1007/S11060-009-0046-7  1
2010 Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 96: 219-30. PMID 19562254 DOI: 10.1007/S11060-009-9950-0  1
2010 Sampson JH, Archer GE, Schmittling R, Herndon JE, Coan AD, Reardon DA, Verdenburgh J, Desjardins A, Dechkovskaia A, McGehee-Norman S, Lally-Goss D, Perry BA, Friedman A, Friedman HS, Bigner DD, et al. Abstract 5611: Interleukin-2 receptor α (IL-2R α/CD25)-specific antibodies eliminate regulatory T-cells (TRegs) and enhance tumor-specific immune responses Cancer Research. 70: 5611-5611. DOI: 10.1158/1538-7445.Am10-5611  1
2010 Cai M, Choi B, Bigner DD, Sampson JH, Kuan C. Abstract 4409: A bispecific T-cell engager effectively eradicates EGFRvIII-expressing glioblastoma multiforme Cancer Research. 70: 4409-4409. DOI: 10.1158/1538-7445.Am10-4409  1
2010 Oh DS, Reardon DA, Prosnitz LR, Gockerman JP, Sampson J, Kirkpatrick JP. Low-dose Whole Brain Radiotherapy followed by Radiosurgery for Primary CNS Lymphoma Achieving Partial Response to Induction Chemotherapy International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.696  1
2010 Ding D, Kanaly CW, Brady ML, Mittermeyer S, Raghavan R, Sampson JH. Convection-enhanced drug delivery to the brain Neuromethods. 45: 291-318. DOI: 10.1007/978-1-60761-529-3_15  1
2009 Sampson JH, Archer GE, Bigner DD, Schmittling RJ, Herndon JE, Davis T, Friedman HS, Keler T, Reardon DA, Mitchell DA. Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2034. PMID 27964629 DOI: 10.1200/Jco.2009.27.15_Suppl.2034  1
2009 Heimberger AB, Archer GE, Mitchell DA, Bigner DD, Schmittling RJ, Herndon JE, Davis T, Friedman HS, Keler T, Reardon DA, Sampson JH. Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2021. PMID 27964605 DOI: 10.1200/Jco.2009.27.15_Suppl.2021  1
2009 Heimberger AB, Kong LY, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Wei J, Qiao W, Schmittling RJ, Archer GE, Sampson JH, Hiraoka N, Priebe W, Fuller GN, Sawaya R. The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. Clinical Neurosurgery. 56: 98-106. PMID 20214040 DOI: 10.1227/01.Neu.0000333524.54656.42  1
2009 Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. British Journal of Cancer. 101: 1986-94. PMID 19920819 DOI: 10.1038/Sj.Bjc.6605412  1
2009 Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DD. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics. 8: 2773-9. PMID 19825799 DOI: 10.1158/1535-7163.Mct-09-0124  1
2009 Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, Sampson JH. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathology (Zurich, Switzerland). 19: 713-23. PMID 19744042 DOI: 10.1111/J.1750-3639.2009.00318.X  1
2009 Boskovitz A, McLendon RE, Okamura T, Sampson JH, Bigner DD, Zalutsky MR. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. Nuclear Medicine and Biology. 36: 659-69. PMID 19647172 DOI: 10.1016/J.Nucmedbio.2009.04.003  1
2009 Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients Expert Opinion On Biological Therapy. 9: 1087-1098. PMID 19591631 DOI: 10.1517/14712590903124346  1
2009 Mitchell DA, Sampson JH. Toward Effective Immunotherapy for the Treatment of Malignant Brain Tumors Neurotherapeutics. 6: 527-538. PMID 19560742 DOI: 10.1016/j.nurt.2009.04.003  1
2009 Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Sampson JH, McLendon RE, Herndon JE, Friedman HS. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. Journal of Neuro-Oncology. 95: 393-400. PMID 19533023 DOI: 10.1007/S11060-009-9937-X  1
2009 Akazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox EA, Sampson JH, Kwatra MM. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. Journal of Neurochemistry. 109: 1079-86. PMID 19519779 DOI: 10.1111/j.1471-4159.2009.06032.x  1
2009 Chino JP, Sampson JH, Tucci DL, Brizel DM, Kirkpatrick JP. Paraganglioma of the head and neck long-term local control with radiotherapy American Journal of Clinical Oncology: Cancer Clinical Trials. 32: 304-307. PMID 19433962 DOI: 10.1097/COC.0b013e318187dd94  1
2009 Wiemels JL, Wilson D, Patil C, Patoka J, McCoy L, Rice T, Schwartzbaum J, Heimberger A, Sampson JH, Chang S, Prados M, Wiencke JK, Wrensch M. IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. International Journal of Cancer. Journal International Du Cancer. 125: 680-7. PMID 19408307 DOI: 10.1002/Ijc.24369  1
2009 Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Friedman HS. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer. 115: 2964-70. PMID 19402172 DOI: 10.1002/Cncr.24336  1
2009 Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro-Oncology. 11: 556-61. PMID 19289491 DOI: 10.1215/15228517-2009-007  1
2009 Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1262-7. PMID 19204199 DOI: 10.1200/Jco.2008.18.8417  1
2009 Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Threatt S, Friedman HS. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1064-8. PMID 19188181 DOI: 10.1158/1078-0432.Ccr-08-2130  1
2009 Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, Mitchell DA, Bigner DD. Proteomic and immunologic analyses of brain tumor exosomes. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 1541-57. PMID 19109410 DOI: 10.1096/Fj.08-122184  1
2009 Nelson JW, Yoo DS, Sampson JH, Isaacs RE, Larrier NA, Marks LB, Yin FF, Wu QJ, Wang Z, Kirkpatrick JP. Stereotactic body radiotherapy for lesions of the spine and paraspinal regions. International Journal of Radiation Oncology, Biology, Physics. 73: 1369-75. PMID 19004569 DOI: 10.1016/J.Ijrobp.2008.06.1949  1
2008 Sampson JH, Archer GE, Bigner DD, Davis T, Friedman HS, Keler T, Mitchell DA, Reardon DA, Sawaya R, Heimberger AB. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2011. PMID 27948414 DOI: 10.1200/Jco.2008.26.15_Suppl.2011  1
2008 Anders CK, Hsu DS, Acharya CR, McLendon R, Sampson JH, Vredenburgh JJ, Satterfield D, Spector N, Potti A, Blackwell KL. A genomic approach to define important and targetable molecular pathways in brain metastasis arising from solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 11041. PMID 27947651 DOI: 10.1200/Jco.2008.26.15_Suppl.11041  1
2008 Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7068-73. PMID 18981004 DOI: 10.1158/1078-0432.Ccr-08-0260  1
2008 Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Sampson JH, Priebe W, Heimberger AB. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5759-68. PMID 18794085 DOI: 10.1158/1078-0432.Ccr-08-0377  1
2008 Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE, Friedman HS, Bigner DD, Sampson JH. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. Journal of Immunological Methods. 339: 74-81. PMID 18775433 DOI: 10.1016/J.Jim.2008.08.004  1
2008 Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Seminars in Immunology. 20: 267-75. PMID 18539480 DOI: 10.1016/J.Smim.2008.04.001  1
2008 Vega EA, Graner MW, Sampson JH. Combating immunosuppression in glioma Future Oncology. 4: 433-442. PMID 18518768 DOI: 10.2217/14796694.4.3.433  1
2008 Everson RG, Graner MW, Gromeier M, Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS, Friedman AH, Bigner DD, Sampson JH. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Review of Anticancer Therapy. 8: 717-32. PMID 18471045 DOI: 10.1586/14737140.8.5.717  1
2008 Mitchell DA, Karikari I, Cui X, Xie W, Schmittling R, Sampson JH. Selective modification of antigen-specific T cells by RNA electroporation Human Gene Therapy. 19: 511-521. PMID 18471037 DOI: 10.1089/hum.2007.115  1
2008 Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-Oncology. 10: 320-9. PMID 18403491 DOI: 10.1215/15228517-2008-012  1
2008 Choi JD, Powers CJ, Vredenburgh JJ, Friedman AH, Sampson JH. Cryptococcal meningitis in patients with glioma: A report of two cases Journal of Neuro-Oncology. 89: 51-53. PMID 18398572 DOI: 10.1007/s11060-008-9581-x  1
2008 Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors Immunological Reviews. 222: 70-100. PMID 18363995 DOI: 10.1111/j.1600-065X.2008.00603.x  1
2008 Selznick LA, Shamji MF, Fecci P, Gromeier M, Friedman AH, Sampson J. Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. Neurosurgical Review. 31: 141-55; discussion 1. PMID 18259789 DOI: 10.1007/S10143-008-0121-0  1
2008 Grossi PM, Ellis MJ, Cummings TJ, Gray LL, Fukushima T, Sampson JH. Cholesterol granuloma of the lateral ventricle. Case report. Journal of Neurosurgery. 108: 357-60. PMID 18240934 DOI: 10.3171/Jns/2008/108/2/0357  1
2008 Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD, Sampson JH. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro-Oncology. 10: 98-103. PMID 18079360 DOI: 10.1215/15228517-2007-046  1
2008 Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology. 10: 10-8. PMID 17951512 DOI: 10.1215/15228517-2007-035  1
2008 Ochiai H, Archer GE, Herndon JE, Kuan CT, Mitchell DA, Bigner DD, Pastan IH, Sampson JH. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Cancer Immunology, Immunotherapy : Cii. 57: 115-21. PMID 17634939 DOI: 10.1007/S00262-007-0363-7  1
2008 Nelson JW, Yoo DS, Sampson JH, Isaacs RE, Larrier NA, Marks LB, Yin FF, Wu QJ, Wang Z, Kirkpatrick JP. Stereotactic Body Radiosurgery of the Spine: The Duke Experience International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.1438  1
2007 Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY, Sherman JW, Husain SR, Puri RK. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery. 61: 1031-7; discussion 1. PMID 18091279 DOI: 10.1227/01.Neu.0000303199.77370.9E  1
2007 Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4722-9. PMID 17947719 DOI: 10.1200/Jco.2007.12.2440  1
2007 Sampson JH, Raghavan R, Brady ML, Provenzale JM, Herndon JE, Croteau D, Friedman AH, Reardon DA, Coleman RE, Wong T, Bigner DD, Pastan I, Rodríguez-Ponce MI, Tanner P, Puri R, et al. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro-Oncology. 9: 343-53. PMID 17435179 DOI: 10.1215/15228517-2007-007  1
2007 Everson RG, Gromeier M, Sampson JH. Viruses in the treatment of malignant glioma Expert Review of Neurotherapeutics. 7: 321-324. PMID 17425484 DOI: 10.1586/14737175.7.4.321  1
2007 Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2158-67. PMID 17404100 DOI: 10.1158/1078-0432.Ccr-06-2070  1
2007 Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 837-44. PMID 17327604 DOI: 10.1200/Jco.2006.08.1117  1
2007 Sampson JH, Raghavan R, Provenzale JM, Croteau D, Reardon DA, Coleman RE, Rodríguez Ponce I, Pastan I, Puri RK, Pedain C. Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. Ajr. American Journal of Roentgenology. 188: 703-9. PMID 17312057 DOI: 10.2214/AJR.06.0428  1
2007 Sampson JH, Brady ML, Petry NA, Croteau D, Friedman AH, Friedman HS, Wong T, Bigner DD, Pastan I, Puri RK, Pedain C. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery. 60: ONS89-98; discussion. PMID 17297371 DOI: 10.1227/01.Neu.0000249256.09289.5F  1
2007 Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. Journal of Neuro-Oncology. 83: 53-60. PMID 17245623 DOI: 10.1007/S11060-006-9302-2  1
2007 Learn CA, Grossi PM, Schmittling RJ, Xie W, Mitchell DA, Karikari I, Wei Z, Dressman H, Sampson JH. Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity Journal of Neuroimmunology. 182: 63-72. PMID 17137636 DOI: 10.1016/j.jneuroim.2006.09.016  1
2007 Soper JT, Spillman M, Sampson JH, Kirkpatrick JP, Wolf JK, Clarke-Pearson DL. High-risk gestational trophoblastic neoplasia with brain metastases: Individualized multidisciplinary therapy in the management of four patients Gynecologic Oncology. 104: 691-694. PMID 17137617 DOI: 10.1016/j.ygyno.2006.10.027  1
2006 Learn CA, Fecci PE, Schmittling RJ, Xie W, Karikari I, Mitchell DA, Archer GE, Wei Z, Dressman H, Sampson JH. Profiling of CD4+, CD8+, and CD4+CD25 +CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers Clinical Cancer Research. 12: 7306-7315. PMID 17189402 DOI: 10.1158/1078-0432.CCR-06-1727  1
2006 Ochiai H, Pernell CT, Archer GE, Chewning TA, McLendon RE, Friedman HS, Sampson JH. Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin. Neurologia Medico-Chirurgica. 46: 485-9; discussion 48. PMID 17062987 DOI: 10.2176/Nmc.46.485  1
2006 Petrella JR, Shah LM, Harris KM, Friedman AH, George TM, Sampson JH, Pekala JS, Voyvodic JT. Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors. Radiology. 240: 793-802. PMID 16857981 DOI: 10.1148/radiol.2403051153  1
2006 Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, Cui X, Cummings TJ, Bigner DD, Gilboa E, Sampson JH. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4294-305. PMID 16857805 DOI: 10.1158/1078-0432.Ccr-06-0053  1
2006 Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, et al. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 912-8. PMID 16741299  1
2006 Kunwar S, Chang SM, Prados MD, Berger MS, Sampson JH, Croteau D, Sherman JW, Grahn AY, Shu VS, Dul JL, Husain SR, Joshi BH, Pedain C, Puri RK. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies Neurosurgical Focus [Electronic Resource].. 20: E15. PMID 16709020  1
2006 Sampson JH, Akabani G, Friedman AH, Bigner D, Kunwar S, Berger MS, Bankiewicz KS. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies Neurosurgical Focus. 20: E14. PMID 16709019 DOI: 10.3171/Foc.2006.20.4.9  1
2006 Raghavan R, Brady ML, Rodríguez-Ponce MI, Hartlep A, Pedain C, Sampson JH. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurgical Focus. 20: E12. PMID 16709017 DOI: 10.3171/foc.2006.20.4.7  1
2006 Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE, Bigner DD, Dranoff G, Sampson JH. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Research. 66: 3294-302. PMID 16540683 DOI: 10.1158/0008-5472.Can-05-3773  1
2006 Ochiai H, Campbell SA, Archer GE, Chewning TA, Dragunsky E, Ivanov A, Gromeier M, Sampson JH. Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1349-54. PMID 16489093 DOI: 10.1158/1078-0432.Ccr-05-1595  1
2006 Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 860-8. PMID 16467100 DOI: 10.1158/1078-0432.Ccr-05-2215  1
2005 Reardon DA, Egorin MJ, Quinn JA, Rich JN, Rich JN, Gururangan S, Gururangan I, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE, Dowell JM, Badruddoja MA, McLendon RE, ... ... Sampson JH, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 9359-68. PMID 16361636 DOI: 10.1200/Jco.2005.03.2185  1
2005 Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7178-87. PMID 16192602 DOI: 10.1200/Jco.2005.06.502  1
2005 Little KM, Friedman AH, Sampson JH, Wanibuchi M, Fukushima T. Surgical management of petroclival meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients. Neurosurgery. 56: 546-59; discussion 5. PMID 15730581 DOI: 10.1227/01.NEU.0000153906.12640.62  1
2005 Sampson JH, Reardon DA, Friedman AH, Friedman HS, Coleman RE, McLendon RE, Pastan I, Bigner DD. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro-Oncology. 7: 90-6. PMID 15701286 DOI: 10.1215/S1152851703000589  1
2005 Prados M, Kunwar S, Lang FF, Ram Z, Westphal M, Barnett G, Sampson JH, Croteau D, Puri RK, investigators fap. Final results of phase I/II studies of IL13-PE38QQR administered intratumorally (IT) and/or peritumorally (PT) via convection-enhanced delivery (CED) in patients undergoing tumor resection for recurrent malignant glioma Journal of Clinical Oncology. 23: 1506-1506. DOI: 10.1200/Jco.2005.23.16_Suppl.1506  1
2005 Sampson JH, Shafman TD, Carter JH, Friedman AH, Seigler HF. Brain metastases from malignant melanoma Textbook of Neuro-Oncology. 430-438. DOI: 10.1016/B978-0-7216-8148-1.50059-0  1
2004 Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD, Gromeier M. Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro-Oncology. 6: 208-17. PMID 15279713 DOI: 10.1215/S1152851703000577  1
2004 Ochiai H, Moore SA, Archer GE, Okamura T, Chewning TA, Marks JR, Sampson JH, Gromeier M. Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4831-8. PMID 15269159 DOI: 10.1158/1078-0432.Ccr-03-0694  1
2004 Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Vredenburgh J, Gururangan S, Provenzale JM, Walker A, Schweitzer H, Bigner DD, Tourt-Uhlig S, Herndon JE, Affronti ML, Jackson S, et al. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro-Oncology. 6: 145-53. PMID 15134629 DOI: 10.1215/S1152851703000498  1
2004 Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE, Dowell JM, Affronti ML, Jackson S, Allen D, et al. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-Oncology. 6: 134-44. PMID 15134628 DOI: 10.1215/S1152851703000413  1
2004 Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3216-24. PMID 15131063 DOI: 10.1158/1078-0432.Ccr-03-0521  1
2004 Sampson JH, Grossi PM, Asaoka K, Fukushima T, Casey KF, Jannetta PJ, Bricolo A, Tew JM. Microvascular Decompression for Glossopharyngeal Neuralgia: Long-term Effectiveness and Complication Avoidance Neurosurgery. 54: 884-890. PMID 15046654  1
2004 Morse MA, Lyerly HK, Clay TM, Abdel-Wahab O, Chui SY, Garst J, Gollob J, Grossi PM, Kalady M, Mosca PJ, Onaitis M, Sampson JH, Seigler HF, Toloza EM, Tyler D, et al. Immunotherapy of surgical malignancies. Current Problems in Surgery. 41: 15-132. PMID 14749625 DOI: 10.1016/S0011384003001321  1
2004 Itharat A, Houghton PJ, Eno-Amooquaye E, Burke PJ, Sampson JH, Raman A. In vitro cytotoxic activity of Thai medicinal plants used traditionally to treat cancer Journal of Ethnopharmacology. 90: 33-38. PMID 14698505 DOI: 10.1016/j.jep.2003.09.014  1
2004 Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, ... ... Sampson JH, et al. Phase II trial of gefitinib in recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 133-42. PMID 14638850 DOI: 10.1200/Jco.2004.08.110  1
2003 Grossi PM, Ochiai H, Archer GE, McLendon RE, Zalutsky MR, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5514-20. PMID 14654531  1
2003 Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Journal of Neuro-Oncology. 65: 27-35. PMID 14649883 DOI: 10.1023/A:1026290315809  1
2003 Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 4247-54. PMID 14519652  1
2003 Mitchell DA, Fecci PE, Sampson JH. Adoptive immunotherapy for malignant glioma Cancer Journal. 9: 157-166. PMID 12952301 DOI: 10.1097/00130404-200305000-00004  1
2003 Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, Bigner DD, Sampson JH. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. Journal of Neuro-Oncology. 64: 161-76. PMID 12952297 DOI: 10.1007/Bf02700031  1
2003 Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 646-51. PMID 12586801 DOI: 10.1200/Jco.2003.01.009  1
2002 Fecci PE, Sampson JH. Clinical immunotherapy for brain tumors Neuroimaging Clinics of North America. 12: 641-664. PMID 12687917 DOI: 10.1016/S1052-5149(02)00027-8  1
2002 Fecci PE, Gromeier M, Sampson JH. Viruses in the treatment of brain tumors Neuroimaging Clinics of North America. 12: 553-570. PMID 12687911 DOI: 10.1016/S1052-5149(02)00028-X  1
2002 Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2277-83. PMID 11980998 DOI: 10.1200/Jco.2002.09.084  1
2002 Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 1389-97. PMID 11870184 DOI: 10.1200/Jco.20.5.1389  1
2002 Wikstrand CJ, Cole VR, Crotty LE, Sampson JH, Bigner DD. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunology, Immunotherapy : Cii. 50: 639-52. PMID 11862416 DOI: 10.1007/S00262-001-0243-5  1
2002 Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery. 50: 158-64; discussion 1. PMID 11844246 DOI: 10.1097/00006123-200201000-00024  1
2001 Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-Oncology. 3: 246-50. PMID 11584894 DOI: 10.1093/Neuonc/3.4.246  1
2000 Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich JN, Sampson J, Pegg AE, Moschel RC, McLendon RE, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 3522-8. PMID 11032594 DOI: 10.1200/jco.2000.18.20.3522  1
2000 Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, Dranoff G, Friedman AH, Friedman HS, Bigner DD. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proceedings of the National Academy of Sciences of the United States of America. 97: 7503-8. PMID 10852962 DOI: 10.1073/Pnas.130166597  1
2000 Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, Bigner DD, Sampson JH. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. Journal of Neuroimmunology. 103: 16-25. PMID 10674985 DOI: 10.1016/S0165-5728(99)00172-1  1
1999 Sampson JH. The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors Neuro-Oncology. 1: 33-42. PMID 11550300 DOI: 10.1093/neuonc/1.1.33  1
1999 Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Reviews. 18: 451-64. PMID 10855788 DOI: 10.1023/A:1006354102377  1
1999 Archer GE, Sampson JH, McLendon RE, Friedman AH, Colvin OM, Rose M, Sands H, McCullough W, Fuchs HE, Bigner DD, Friedman HS. Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. Journal of Neuro-Oncology. 44: 233-41. PMID 10720203 DOI: 10.1023/A:1006304424346  1
1999 Sampson JH, Archer GE, Villavicencio AT, McLendon RE, Friedman AH, Bishop WR, Bigner DD, Friedman HS. Treatment of neoplastic meningitis with intrathecal temozolomide. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 5: 1183-8. PMID 10353755 DOI: 10.1097/00006123-199909000-00095  1
1998 Ashley DM, Sampson JH, Archer GE, Hale LP, Bigner DD. Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model. Journal of Neuroimmunology. 86: 46-52. PMID 9655471 DOI: 10.1016/S0165-5728(98)00017-4  1
1997 Sampson JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP, Bigner DD. Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery. 41: 1365-72; discussion . PMID 9402588 DOI: 10.1097/00006123-199712000-00024  1
1997 Ashley DM, Sampson JH, Archer GE, Batra SK, Bigner DD, Hale LP. A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. Journal of Neuroimmunology. 78: 34-46. PMID 9307226 DOI: 10.1016/S0165-5728(97)00080-5  1
1996 Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proceedings of the National Academy of Sciences of the United States of America. 93: 10399-404. PMID 8816812 DOI: 10.1073/Pnas.93.19.10399  1
1995 Spiegel DA, Sampson JH, Richardson WJ, Friedman AH, Rossitch E, Hardaker WT, Seigler HF. Metastatic melanoma to the spine. Demographics, risk factors, and prognosis in 114 patients. Spine. 20: 2141-6. PMID 8588172  1
1995 Gabriel EM, Sampson JH, Dodd LG, Turner DA. Glomus jugulare tumor metastatic to the sacrum after high-dose radiation therapy: case report. Neurosurgery. 37: 1001-5. PMID 8559322 DOI: 10.1227/00006123-199511000-00022  1
1995 Sampson JH, Cashman RE, Nashold BS, Friedman AH. Dorsal root entry zone lesions for intractable pain after trauma to the conus medullaris and cauda equina. Journal of Neurosurgery. 82: 28-34. PMID 7815130 DOI: 10.3171/jns.1995.82.1.0028  1
Show low-probability matches.